Icrucumab is under investigation in clinical trial NCT01111604 (A Study of IMC-1121B or IMC-18F1 in Colorectal Cancer).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Icrucumab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Icrucumab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Icrucumab. |
| Estrone | Estrone may increase the thrombogenic activities of Icrucumab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Icrucumab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Icrucumab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Icrucumab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Icrucumab. |
| Estriol | Estriol may increase the thrombogenic activities of Icrucumab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Icrucumab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Icrucumab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Icrucumab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Icrucumab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Icrucumab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Icrucumab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Icrucumab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Icrucumab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Icrucumab. |
| Equol | Equol may increase the thrombogenic activities of Icrucumab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Icrucumab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Icrucumab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Icrucumab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Icrucumab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Icrucumab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Icrucumab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Icrucumab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Icrucumab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Icrucumab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Icrucumab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Icrucumab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Icrucumab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Icrucumab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Icrucumab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Icrucumab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Icrucumab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Icrucumab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Icrucumab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Icrucumab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Icrucumab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Icrucumab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Icrucumab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Icrucumab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Icrucumab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Icrucumab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Icrucumab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Icrucumab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Icrucumab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Icrucumab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Icrucumab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Icrucumab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Icrucumab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Icrucumab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Icrucumab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Icrucumab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Icrucumab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Icrucumab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Icrucumab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Icrucumab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Icrucumab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Icrucumab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Icrucumab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Icrucumab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Icrucumab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Icrucumab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Icrucumab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Icrucumab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Icrucumab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Icrucumab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Icrucumab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Icrucumab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Icrucumab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Icrucumab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Icrucumab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Icrucumab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Icrucumab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Icrucumab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Icrucumab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Icrucumab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Icrucumab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Icrucumab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Icrucumab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Icrucumab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Icrucumab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Icrucumab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Icrucumab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Icrucumab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Icrucumab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Icrucumab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Icrucumab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Icrucumab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Icrucumab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Icrucumab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Icrucumab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Icrucumab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Icrucumab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Icrucumab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Icrucumab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Icrucumab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Icrucumab. |
| Lumiliximab | The risk or severity of adverse effects can be increased when Lumiliximab is combined with Icrucumab. |